MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in public...
$143,896K
Proceeds from senior
secured term loan, net of...
$97,503K
Proceeds from issuance of
common stock in public...
$20,218K
Proceeds from stock
option exercises
$2,603K
(116.56%↑ Y/Y)
Proceeds from issuance of
common stock for cash...
$292K
(105.63%↑ Y/Y)
Net cash provided by
financing activities
$243,264K
(22.18%↑ Y/Y)
Canceled cashflow
$21,248K
Net decrease in cash
and cash...
$25,489K
(307.18%↑ Y/Y)
Canceled cashflow
$217,775K
something is missing
-$20,218K
Payment of debt issuance
costs with third...
$1,015K
Payment of shelf
offering costs
$15K
(-73.68%↓ Y/Y)
Maturities of marketable
securities
$325,000K
(195.45%↑ Y/Y)
Upfront payment
pursuant to fourth...
-$200,000K
Stock-based compensation
$7,355K
(-10.28%↓ Y/Y)
Accounts payable and
accrued liabilities
$3,667K
(-51.29%↓ Y/Y)
Prepaid, other current
assets, and other assets
-$1,958K
(-173.66%↓ Y/Y)
Amortization of debt discount
and issuance costs...
$126K
Accrued interest
receivable
-$47K
(-840.00%↓ Y/Y)
Depreciation and
amortization
$5K
(-83.87%↓ Y/Y)
Net cash used in
investing activities
-$185,219K
(-36.43%↓ Y/Y)
Net cash used in
operating activities
-$32,556K
(56.97%↑ Y/Y)
Canceled cashflow
$325,000K
Canceled cashflow
$213,158K
Purchases of marketable
securities
$310,219K
(26.23%↑ Y/Y)
Net loss
-$241,071K
(-182.00%↓ Y/Y)
Upfront payment
pursuant to fourth...
$200,000K
Accretion of discount on
held-to-maturity securities
$4,643K
(41.77%↑ Y/Y)
Back
Back
Cash Flow
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)
source: myfinsight.com